When to Discontinue Sertraline
For a first episode of major depression, continue sertraline for at least 4 months after achieving remission, with guideline consensus supporting 6-9 months of maintenance therapy. 1
Duration Based on Episode History
First Episode Depression
- Minimum duration: 4 months post-remission 1
- Optimal duration: 6-9 months after symptom resolution 2
- This timeframe reduces relapse risk while avoiding unnecessarily prolonged exposure to adverse effects
Recurrent Depression
- Continue for 2+ years or consider indefinite maintenance 2
- Recent primary care research demonstrates substantial relapse risks with discontinuation in recurrent depression 3
- Limited evidence supports benefits of cessation in patients with multiple prior episodes 3
- The benefit-to-risk ratio favors continuation when patients have experienced ≥2 prior episodes
Clinical Scenarios Requiring Discontinuation
Discontinue immediately if:
- Serotonin syndrome develops (tremor, rigidity, hyperthermia, autonomic instability) 4
- Need to initiate MAOI therapy (linezolid, IV methylene blue) 4
- Persistently worsening depression or emergent suicidality despite adequate trial 4
- Intolerable adverse effects outweigh therapeutic benefits 5
How to Discontinue: Tapering Protocol
Never stop abruptly - this precipitates withdrawal symptoms in >50% of patients 6. The FDA label explicitly warns against abrupt discontinuation 4.
Standard-Risk Patients
For patients on sertraline <12 months with no prior withdrawal difficulties:
- Reduce dose by 25-50% every 2 weeks 5
- Example: 100 mg → 50 mg (2 weeks) → 25 mg (2 weeks) → stop
- Total taper duration: 4-6 weeks
High-Risk Patients
Higher risk includes: longer treatment duration (>12 months), higher doses, prior withdrawal symptoms, or concurrent anxiety disorders 5, 6:
- Use hyperbolic (not linear) dose reductions 7
- Taper over months, potentially reaching doses as low as 1 mg 5
- May require liquid formulations or compounded "mini doses" 5
- Reduce by smaller decrements as dose decreases (e.g., 100→75→50→37.5→25→18.75→12.5→6.25→3→1 mg)
- Follow-up every 2-4 weeks during taper 6
Rationale: PET imaging shows SSRI receptor occupancy follows hyperbolic kinetics - linear dose reductions cause exponentially larger biological effects at lower doses, triggering withdrawal 7.
Distinguishing Withdrawal from Relapse
Withdrawal Symptoms (appear within days of dose reduction):
- Dizziness, "brain zaps," paresthesias
- Flu-like symptoms (myalgia, fatigue)
- Gastrointestinal distress
- Irritability, anxiety (but not sustained low mood)
- Typically resolve within 2 weeks if dose held stable 5, 6
Relapse (appears weeks after discontinuation):
- Return of core depressive symptoms (anhedonia, hopelessness)
- Sustained low mood >2 weeks
- Neurovegetative symptoms (sleep/appetite changes)
- Functional impairment matching original presentation
Critical pitfall: Withdrawal-induced anxiety/irritability is commonly misdiagnosed as relapse, leading to unnecessary long-term medication 6. If uncertain, pause taper for 2-4 weeks - withdrawal symptoms will improve, relapse symptoms will persist or worsen.
Monitoring During Discontinuation
- Reassess every 2-4 weeks during active taper 6
- Use standardized scales (PHQ-9, HAMD) to objectively track symptoms
- If withdrawal symptoms emerge: pause taper, consider returning to last tolerated dose, then slow taper further 6
- Annual reassessment of indication is reasonable for long-term users 2
Special Considerations
Pregnancy/Breastfeeding: Sertraline is among preferred agents during breastfeeding due to low milk transfer 1. Discontinuation decisions must weigh maternal mental health stability against theoretical fetal/neonatal risks - untreated depression carries its own morbidity.
Older Adults: Sertraline remains a preferred agent in this population 1. However, older adults may experience more pronounced withdrawal symptoms requiring slower tapers 5.